 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 5 | 8 | | 1994 | 1 | 1 | 2 | | 1995 | 3 | 1 | 4 | | 1996 | 10 | 3 | 13 | | 1997 | 4 | 5 | 9 | | 1998 | 3 | 6 | 9 | | 1999 | 5 | 5 | 10 | | 2000 | 7 | 10 | 17 | | 2001 | 10 | 6 | 16 | | 2002 | 10 | 6 | 16 | | 2003 | 12 | 9 | 21 | | 2004 | 15 | 9 | 24 | | 2005 | 15 | 10 | 25 | | 2006 | 6 | 4 | 10 | | 2007 | 6 | 10 | 16 | | 2008 | 8 | 13 | 21 | | 2009 | 12 | 15 | 27 | | 2010 | 14 | 7 | 21 | | 2011 | 11 | 12 | 23 | | 2012 | 9 | 7 | 16 | | 2013 | 17 | 8 | 25 | | 2014 | 17 | 15 | 32 | | 2015 | 11 | 5 | 16 | | 2016 | 8 | 12 | 20 | | 2017 | 14 | 6 | 20 | | 2018 | 8 | 6 | 14 | | 2019 | 7 | 9 | 16 | | 2020 | 14 | 9 | 23 | | 2021 | 9 | 7 | 16 | | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology. 2022 12; 76(6):1862-1879.
-
Cannon LA, Wenderfer SE, Lewandowski LB, Cooper JC, Goilav B, Knight AM, Hersh AO, Ardoin SP, Sadun RE. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. J Rheumatol. 2022 06; 49(6):607-614.
-
Sprague KA, Sivesind TE, Szeto MD, Dellavalle RP, Kirtschig G. From the Cochrane Library: Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 2022 06; 86(6):e273-e274.
-
Iliopoulou VN, Charkoftaki G, Cooper JC, Dokoumetzidis A, Joy MS. Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis. J Pharm Pharmacol. 2021 Dec 07; 73(12):1683-1692.
-
Liu YH, Guo YC, Lin LY, Tsai CP, Fuh JL, Wang YF, Chen SP, Wu HM, Yu KW, Lin KP, Wang SJ, Liao YC, Lee YC. Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder. J Formos Med Assoc. 2022 Sep; 121(9):1647-1656.
-
Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol. 2021 10 01; 321(4):F505-F516.
-
Kemme S, Feldman AG, Mack C. Severe Seronegative Hepatitis-associated Aplastic Anemia: Looking for the Best Treatment. J Pediatr Gastroenterol Nutr. 2021 08 01; 73(2):e48.
-
Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, Santomasso BD, Faleck DM, Hellmann MD. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764.
-
Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 07 01; 78(7):787-788.
-
Burkhard A, Toliver J, Rascati K. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. J Manag Care Spec Pharm. 2021 Jul; 27(7):915-923.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|